NCT04167280View on ClinicalTrials.gov

Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

March 13, 2020

Study Completion Date

March 13, 2020

Conditions
Asthma
Interventions
DRUG

Ipratropium Metered Dose Inhaler

MDI to deliver 20mcg per puff ipratropium bromide

DRUG

placebo metered dose inhaler

matched MDI to deliver inactive drug

Trial Locations (1)

S7N 0W8

University of Saskatchewan, Saskatoon

All Listed Sponsors
lead

University of Saskatchewan

OTHER

NCT04167280 - Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma | Biotech Hunter | Biotech Hunter